|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||20.62 - 21.06|
|52 Week Range||16.26 - 21.28|
|Beta (3Y Monthly)||0.92|
|PE Ratio (TTM)||22.67|
|Forward Dividend & Yield||0.36 (1.74%)|
|1y Target Est||17.90|
(Bloomberg) -- Smiths Group Plc shares rose to their highest in more than a year on Monday as analysts threw support behind a potential sale of its medical-equipment business.Blackstone Group Inc. and Cinven are among buyout firms weighing bids for the U.K. industrial conglomerate’s unit, people familiar with the matter said last week. Smiths Group had said previously that it was planning to separate the medical business via a listing after talks with another suitor collapsed.A sale would be a cleaner exit than spinning off another traded business, Liberum Capital Ltd. analyst Ryan Gregory said in a note. A deal could value the medical unit at at least 3 billion pounds ($3.6 billion) based on peers’ multiples, money that could be used to strengthen Smiths Group’s remaining business, Bloomberg Intelligence analyst Johnson Imode said in a report on Friday.While the focus has been the listing, Smiths Group is open to considering offers, the people had said. The company may wait until it has a better view on potential equity market valuations before seriously engaging with any suitors, one of the people said. The unit makes devices such as patient monitors and drug delivery systems that are used in ambulances, hospitals and care homes.The stock gained as much as 1.7% to 1,698 pence, the highest intraday level since July 2018. It was trading 0.8% higher at 12:08 p.m. London time on Monday, giving the company a market value of about 6.7 billion pounds. The shares had gained 1.9% on Friday after Bloomberg News’s report.(Updates share price in final paragraph)\--With assistance from Tom Lavell.To contact the reporters on this story: David Hellier in London at firstname.lastname@example.org;Dinesh Nair in London at email@example.com;Sarah Syed in London at firstname.lastname@example.orgTo contact the editors responsible for this story: Dinesh Nair at email@example.com, Amy ThomsonFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Cardlytics, Inc. (CDLX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who really controls Smiths Group plc (LON:SMIN), then you'll have to look at the...
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll look at Smiths Group plc's (LON:SMIN) P/E ratio and reflect on what it tells us about the company's share price. Looking at earni...
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Smiths Group plc (LON:SMIN), with a market capitalization of UK£5.7b, rarely draw their attention from the investingRead More...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Andy Smith has been the CEO of Read More...
Today we'll look at Smiths Group plc (LON:SMIN) and reflect on its potential as an investment. Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us Read More...
Since Smiths Group plc (LON:SMIN) released its earnings in July 2018, the consensus outlook from analysts appear fairly confident, with profits predicted to increase by 30% next year against the Read More...
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health to Read More...
Having tried and failed to sell its medical business three times in recent years, Britain's Smiths Group Plc is planning to offload the division by splitting it off or taking it public. The medical business, which makes syringe pumps, has been a drag.